Phenotypic and genotypic characterization of Neisseria gonorrhoeae isolates among individuals at high risk for sexually transmitted diseases in Zurich,Switzerland

Abstract

Background

While ceftriaxone resistance remains scarce in Switzerland, global Neisseria gonorrhoeae (NG) antimicrobial resistance poses an urgent threat. This study describes clinical characteristics in MSM (men who have sex with men) diagnosed with NG infection and analyses NG resistance by phenotypic and genotypic means.

Methods

Data of MSM enrolled in three clinical cohorts with a positive polymerase chain reaction test (PCR) for NG were analysed between January 2019 and December 2021 and linked with antibiotic susceptibility testing. Bacterial isolates were subjected to whole genome sequencing (WGS).

Results

Of 142 participants, 141 (99%) were MSM and 118 (84%) living with HIV. Participants were treated with ceftriaxone (N = 79), azithromycin (N = 2), or a combination of both (N = 61). No clinical or microbiological failures were observed. From 182 positive PCR samples taken, 23 were available for detailed analysis. Based on minimal inhibitory concentrations (MICs), all isolates were susceptible to ceftriaxone, gentamicin, cefixime, cefpodoxime, ertapenem, zoliflodacin, and spectinomycin. Resistance to azithromycin, tetracyclines and ciprofloxacin was observed in 10 (43%), 23 (100%) and 11 (48%) of the cases, respectively. Analysis of WGS data revealed combinations of resistance determinants that matched with the corresponding phenotypic resistance pattern of each isolate.

Conclusion

Among the MSM diagnosed with NG mainly acquired in Switzerland, ceftriaxone MICs were low for a subset of bacterial isolates studied and no treatment failures were observed. For azithromycin, high occurrences of in vitro resistance were found. Gentamicin, cefixime, cefpodoxime, ertapenem, spectinomycin, and zoliflodacin displayed excellent in vitro activity against the 23 isolates underscoring their potential as alternative agents to ceftriaxone.

Keywords

Antimicrobial susceptibility ceftriaxone whole genome sequencing genomic epidemiology

Get full access to this article

View all access options for this article.

References

Rowley

Vander Hoorn

Korenromp

, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates. Bull World Health Organ 2019; 97(8): 548–562P.

Prevention . Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56(14): 332–336.

Ohnishi

Golparian

Shimuta

, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55(7): 3538–3545.

Kovari

de Melo Oliveira

Hauser

, et al. Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012. BMC Infect Dis 2013; 13: 603.

Unemo

Golparian

Nicholas

, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56(3): 1273–1280.

Unemo

Golparian

Stary

, et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria. Euro Surveill. 2011; 16(43): 19998.

Swiss Society for Infectious Diseases current guideline on the management of Neisseria gonorrhoeae infections , last validation on January 1st 2023. Available online at https://ssi.guidelines.ch/guideline/2272

Centers for Disease Control and Prevention (CDC) . Sexually transmitted infections treatment guidelines 2021. Morbidity and mortality weekly report july 23, 2021. Available at: https://www.cdc.gov/std/treatment-guidelines/default.htm

Fifer

Saunders

Soni

, et al. 2018 UK National guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS 2020; 31(1): 4–15.

10.

Swiss

HIVCS

Schoeni-Affolter

Ledergerber

, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010; 39(5): 1179–1189.

11.

Braun

Marzel

Steffens

, et al. High rates of subsequent asymptomatic sexually transmitted infections and risky sexual behavior in patients initially presenting with primary human immunodeficiency virus-1 infection. Clin Infect Dis 2018; 66(5): 735–742.

12.

Hampel

. A multicenter, observational cohort to study the characteristics of individuals asking for pre-exposure prophylaxis (PrEP) and the incidence of HIV and STIs: «The Swiss PrEPared Study» 2021. Available from: https://www.ebpi.uzh.ch/en/translational_research/chronic_conditions_health/prepared.html

13.

Lagacé-Wiens

PRS

Adam

Laing

, et al. Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential. J Antimicrob Chemother 2017; 72(8): 2273–2277.

14.

Brown

Krysiak

Kamanga

, et al. Neisseria gonorrhoeae antimicrobial susceptibility in lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37(3): 169–172.

15.

Yang

Yan

. Antibiotic resistance and treatment options for multidrug-resistant gonorrhea. Infectious Microbes & Diseases 2020; 2(2): 67–76.

16.

Taylor

Marrazzo

Batteiger

, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med 2018; 379(19): 1835–1845.

17.

Lauener

Imkamp

Lehours

, et al. Genetic determinants and prediction of antibiotic resistance phenotypes in Helicobacter pylori. J Clin Med. 2019; 8(1): 53.

18.

McArthur

Waglechner

Nizam

, et al. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother 2013; 57(7): 3348–3357.

19.

Team

. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2020. Available from: https://www.r-project.org/index.html

20.

Jolley

Bray

Maiden

MCJ

. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 2018; 3: 124.

21.

Lou

, et al. Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in nanjing, China, 2014 to 2018. Antimicrob Agents Chemother. 2021; 65(3): 00863-20–20.

22.

de Vries

HJC

de Laat

Jongen

, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis 2022; 22(5): 706–717.

23.

Golparian

Fernandes

Ohnishi

, et al.

In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?

Antimicrob Agents Chemother 2012; 56(5): 2739–2742.

24.

Bradford

Miller

O'Donnell

, et al. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis 2020; 6(6): 1332–1345.

25.

Unemo

Ahlstrand

Sanchez-Buso

, et al. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries. J Antimicrob Chemother 2021; 76(5): 1221–1228.

26.

Chen

McNulty

Avery

, et al. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial. Lancet Infect Dis 2019; 19(8): 833–842.

27.

Dona

Low

Golparian

, et al. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. Expert Rev Mol Diagn 2017; 17(9): 845–859.

28.

Unemo

Shafer

. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014; 27(3): 587–613.

29.

Eyre

De Silva

Cole

, et al. WGS to predict antibiotic MICs for Neisseria gonorrhoeae. J Antimicrob Chemother 2017; 72(7): 1937–1947.

30.

Braun

Marzel

Steffens

, et al. High rates of subsequent asymptomatic STIs and risky sexual behavior in patients initially presenting with primary HIV-1 infection. Clin Infect Dis. 2018; 66(5): 735–742.

31.

Ring

Balakrishna

Imkamp

, et al. High rates of asymptomatic mycoplasma genitalium infections with high proportion of genotypic resistance to first-line macrolide treatment among men who have sex with men enrolled in the Zurich primary HIV infection study. Open Forum Infect Dis 2022; 9(6): ofac217.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

3.56 MB